Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 13/20 | 1.00 |
| ▸ | ABL1 | P00519 | 11/20 | 1.00 |
| ▸ | BCR | P11274 | 8/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 5/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 0.84 |
| ▸ | PRKCA | P17252 | 1/20 | 0.84 |
| ▸ | KIT | P10721 | 7/20 | 0.82 |
| ▸ | KDR | P35968 | 1/20 | 0.74 |
| ▸ | ABL2 | P42684 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8282185 | 0.96 | PDGFRA (0.93) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL1656154 | 0.94 | PDGFRA (0.90) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL11932096 | 0.93 | PDGFRA (0.86) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL9820 | 0.93 | PDGFRA (1.00) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL13498211 | 0.92 | PDGFRA (0.88) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL3055349 | 0.92 | PDGFRA (0.89) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL9782 | 0.92 | PDGFRA (1.00) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL29498750 | 0.92 | PDGFRA (1.00) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL3219611 | 0.91 | PDGFRA (0.83) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL11927842 | 0.91 | ABL1 (1.00) | PDGFRAABL1BCRPDGFRBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112110906-A | Novel use of conjugates | 中山万汉制药有限公司 | 2020-12-22 | — | — | CN | claimed |
| CN-112079821-A | Conjugate formed by orlistat and phenylaminopyrimidine compound and preparation method and application thereof | 中山万汉制药有限公司 | 2020-12-15 | — | — | CN | claimed |
| CN-112043708-A | Anti-hepatitis B use of conjugates | 中山万汉制药有限公司 | 2020-12-08 | — | — | CN | claimed |
| EP-1721609-A2 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC Biotech AG (DE) | 2006-11-15 | — | — | EP | claimed |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2006-09-28 | — | — | US | claimed |
| EP-1395261-B1 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | GPC BIOTECH AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005065074-A2 | PROTECTION OF TISSUES AND CELLS FROM CYTOTOXIC EFFECTS OF IONIZING RADIATION BY ABL INHIBITORS | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-07-21 | — | — | WO | claimed |
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2003-09-18 | — | — | US | claimed |
| EP-0564409-B1 | Pyrimidin derivatives and process for their preparation | NOVARTIS AG (CH) | 2000-01-19 | — | — | EP | claimed |
| US-5521184-A | ANTITUMOR AGENTS; imatinib mesylate | CIBA-GEIGY CORPORATION (US) | 1996-05-28 | — | — | US | claimed |
| EP-0564409-A1 | Pyrimidin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-10-06 | — | — | EP | claimed |
| CN-112110906-A | Novel use of conjugates | 中山万汉制药有限公司 | 2020-12-22 | — | — | CN | disclosed |
| CN-112079821-A | Conjugate formed by orlistat and phenylaminopyrimidine compound and preparation method and application thereof | 中山万汉制药有限公司 | 2020-12-15 | — | — | CN | disclosed |
| CN-112043708-A | Anti-hepatitis B use of conjugates | 中山万汉制药有限公司 | 2020-12-08 | — | — | CN | disclosed |
| US-20130338168-A1 | Combinations of JAK Inhibitors | NOVARTIS AG (CH) | 2013-12-19 | — | — | US | disclosed |
| WO-2005051229-A2 | DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME | AVANTEC VASCULAR CORPORATION (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050125054-A1 | Devices delivering therapeutic agents and methods regarding the same | AVANTEC VASCULAR CORPORATION (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2004010900-A1 | DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME | AVANTEC VASCULAR CORPORATION (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2003-09-18 | — | — | US | disclosed |
| US-5521184-A | ANTITUMOR AGENTS; imatinib mesylate | CIBA-GEIGY CORPORATION (US) | 1996-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | PRNP, PPM1D, PPM1F | PDGFRA 2586/4885ABL1 901/4885BCR 1338/4885 |
| US-20130338168-A1 | Combinations of JAK Inhibitors | JAK2, JAK3, JAK1 | PDGFRA 44/4885ABL1 5/4885BCR 31/4885 |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | PRNP, PPM1D, PPM1F | PDGFRA 2913/4885ABL1 904/4885BCR 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.